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Marbofloxacin is a fluoroquinolone specially developed for use in veterinary medicine
with broad-spectrum antibacterial activity. The objective of our study was to re-evaluate
in vivo antimicrobial activity of marbofloxacin against Pasteurella multocida using
subcutaneously implanted tissue cages in calves. Calves were infected by direct
injection into tissue cages with P. multocida(type B, serotype 2), then intramuscularly
received a range of marbofloxacin doses 24 h after inoculation. The ratio of
24 h area under the concentration-time curve divided by the minimum inhibitory
concentration or the mutant prevention concentration (AUC24 h/MIC or AUC24 h/MPC)
was the pharmacokinetic-pharmacodynamic (PK/PD) index that best described the
effectiveness of marbofloxacin against P. multocida (R2 = 0.8514) by non-linear
regression analysis. Marbofloxacin exhibited a good antimicrobial activity in vivo. The
levels of AUC24 h/MIC and AUC24 h/MPC that produced 50% (1.5log10 CFU/mL
reduction) and 90% (3log10 CFU/mL reduction) of maximum response were 18.60
and 50.65 h, 4.67 and 12.89 h by using sigmoid Emax model WINNONLIN software,
respectively. The in vivo PK/PD integrated methods by tissue cage model display the
advantage of the evaluation of antimicrobial activity and the optimization of the dosage
regimen for antibiotics in the presence of the host defenses, especially in target animal
of veterinary interest.
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Introduction
To optimize antimicrobial therapy that maximizes eﬃcacy and minimizes selection of resistance,
the pharmacokinetics (PKs) and pharmacodynamics (PDs) characteristics need to be integrated.
Recently, a variety of in vitro and animal models that fractionated dosage regimens showed
that patterns of antimicrobial activity can be divided into two major patterns: time-dependent
killing and concentration-dependent killing (Jacobs, 2001; Toutain et al., 2002; Drusano, 2004).
Time-dependent killing is characteristic of β-lactams, macrolides, and clindamycin, and seeks
to optimize the duration of exposure of a pathogen to an antimicrobial. Their major PK/PD
parameter correlating with eﬀectiveness is the percentage of the dosing interval that the antibiotic
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concentration exceeds the minimum inhibitory concentration
(%T > MIC). The concentration-dependent killing, such
as quinolones and aminoglycosides, seeks to maximize
antimicrobial concentration, and their major PK/PD parameter
correlating with eﬀectiveness is the ratio of 24 h area under the
concentration-time curve or the peak antibiotic concentration
divided by major susceptible cell (MIC; AUC24 h/MIC or
Cmax/MIC).
Many in vitro and in vivo studies have demonstrated that
ﬂuoroquinolone-resistant subpopulations are selectively
enriched in the mutant selection window (MSW), the
concentration range between MIC and mutant prevention
concentration (MPC; Cui et al., 2006; Olofsson et al., 2006;
Drlica and Zhao, 2007). The lower boundary of the MSW is
approximately the minimal concentration that inhibits the
growth of the MICs. And the upper boundary is the MPC,
deﬁned as the lowest antibiotic concentration that prevents
growth of the least-susceptible single-step mutant subpopulation
among a large (1010 cfu) bacterial population (Drlica and
Zhao, 2007). Consequently, recent studies have proposed that
MPC-based PK/PD indices such as AUC24 h/MPC or Cmax/MPC
are more appropriate than MIC-based indices for predicting
mutant-restricting ﬂuoroquinolone doses (Olofsson et al., 2006;
Liang et al., 2011), because MPC is a direct measure of mutant
subpopulation susceptibility while MIC is not, and correlates
poorly with MPC (Liang et al., 2011). Thus, MPC-based PK/PD
indices can be very useful PD parameters for optimization of
antimicrobial therapy.
Recently, a variety of models have been developed to study
the relationship between the PKs and PDs. However, each model
has its own limitations, e.g., for ex vivo PK/PD integrated
model, there is continuous exposure to static concentration
of agent for a deﬁned time(24 h), which does not mimic
the concentration of antibacterial decline in animals for body
clearance and drug metabolism(Xiao et al., 2015). In vitro
models do not account for eﬀects of interaction between the
host and the infecting organism (MacGowan and Bowker,
2002). The infection models in small rodents (mice, rats or
rabbits) are hampered by diﬀerences in PK parameters between
small rodents and larger animals in that they may exist in
complicate extrapolation of results to the clinical situation
(Zak and O’Reilly, 1991). Nevertheless, tissue cages implanted
subcutaneously attract some attention for PKs and PDs studies,
especially in a target animal of veterinary interest (Clarke,
1989). Because subcutaneously implanted tissue cages allow for
repeated sampling, this model has been used extensively to
study the distribution of antimicrobials(Clarke, 1989) and ex vivo
antibacterial eﬀectiveness in animal species of direct veterinary
interest (Aliabadi and Lees, 2002; Potter et al., 2013; Shan et al.,
2014). In addition, tissue cage model has been used to contain an
infection to allow for in vivo studies of antibacterial eﬀectiveness
(Greko et al., 2003a,b) and MSW studies in presence of the
host defenses (Zhao and Drlica, 2001; Cui et al., 2006; Ni et al.,
2014).
Marboﬂoxacin, a synthetic third-generation ﬂuoroquinlone, is
speciﬁcally developed for individual veterinary treatment with a
broad spectrum of activity against most gram negative bacteria,
gram positive bacteria, mycoplasmas, and some intracellular
pathogens such as Chlamydia and Brucella species (Spreng et al.,
1995). For antimicrobial activity properties of marboﬂoxacin,
studies reported the values of AUC24h/MIC required three
levels of antibacterial activity, e.g., bacteriostatic, bactericidal
and virtual eradication by ex vivo PK/PD integrated model in
diﬀerent biological ﬂuids, respectively, in species of veterinary
interest(Aliabadi and Lees, 2002; Sidhu et al., 2011; Shan et al.,
2014). However, to our knowledge, in vivo antibacterial activity
of marboﬂoxacin against Pasteurella multocida has not been
reported in target animal-calves.
The main goal of our study was to re-evaluate in vivo
antimicrobial activity of marboﬂoxacin against P. multocida
based on MIC and MPC in a tissue-cage model in calves.
Materials and Methods
Antimicrobial Agent
Marboﬂoxacin was used as 10% injectable aqueous solution
obtained from Veterinary Pharmaceutical Corporation
(Yuanzhen Co., Ltd, Hebei, China). Marboﬂoxacin standard was
purchased from Dr.Ehenstorfer GmbH Company (Germany)
and oﬂoxacin was acquired from the National Institute for Food
and Drug Control (Beijing, China).
Bacterial Strain
Strain CVCC1669 (type B, serotype 2) of P. multocida was
obtained from the China Veterinary Culture Collection Centre
(Beijing, China).The original bacterial culture had been isolated
from a calve that died of hemorrhagic septicemia in the United
States. The organism was grown, sub-cultured and quantiﬁed
in Mueller–Hinton  Broth (Becton Dickinson, Sparks, MD,
USA) and Tryptic Soy Agar (Guangdong Huaikai Microbial
Sci. & Tech. Co., Ltd, Guangzhou, China) supplemented with
deﬁbrinated sheep blood (BTSA) at a 5% level.
Tissue-Cage Infection Model
Two sterile golf practice wiﬄe balls (43 mm in diameter, with
a volume of 34 ml, as shown in Figure 1) were implanted
subcutaneously in calves, after sedation and local anesthesia.
The procedures were as described elsewhere (Aliabadi and Lees,
2002; Greko et al., 2003a). After surgery, all calves were treated
with intramuscular penicillin (160000 IU/kg) twice a day for
3–5 days to prevent infection. By 4 weeks after implantation,
each tissue-cage had become sealed with a thin layer of
connective tissue and ﬁlled with clear, yellowish tissue cage
ﬂuid (TCF). Sampling of TCF was performed by percutaneous
puncture. Sterility of TCF was assessed by aerobic and anaerobic
culture of samples taken from each cage immediately before
the experiments. Approximately 5 × 106 CFU of exponentially
growing P. multocida culture was suspended in 100 μl of sterile
isotonic saline, and then injected into the pre-implanted each
wiﬄe ball.
Tissue cage ﬂuid was sampled after inoculation(−24 h)
corresponding to the time of the injection of drug (0 h) and 3,
6, 9, and 24 h after administration. Each sample (50 μl) was
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FIGURE 1 | The tissue cages used in in vivo antimicrobial activity of
marbofloxacin against Pasteurella multocida in calves.
subjected to 10-fold serial dilutions using 0.9% NaCl. Twenty
ﬁve micro liter of each dilution was plated onto quadrants of
BTSA agar. The plates were then incubated at 37◦C overnight and
viability counts were examined. The limit of detection (LOD) was
400 CFU/mL.
In Vitro Susceptibility Studies
The MIC value was determined in TCF by a broth microdilution
assay based on Clinical and Laboratory Standards Institute
(CLSI) reference methods using the following two overlapping
sets of twofold serial dilutions to improve accuracy:
0.0125–0.4 μg/mL and 0.0182–0.3 μg/mL.
The MPC value was determined as described elsewhere
(Campion et al., 2004; Ferran et al., 2011). Single bacterial colony
from overnight growth on Tryptic Soy Agar supplemented with
deﬁbrinated sheep blood (BTSA) was grown for 5 h at 37◦C in
Mueller–Hinton  Broth, concentrated by centrifugation, and
re-suspended in Mueller–Hinton  to a ﬁnal concentrations of
∼3 × 1010 CFU/mL. Samples (100 μl) were then plated onto
Mueller–Hinton Agar (MHA; supplemented with deﬁbrinated
sheep blood) containing various concentrations of marboﬂoxacin
obtained by successive twofold dilutions, inoculated plates
were incubated for 24 h at 37◦C and then examined for
regrowth. All plates were re-incubated for an additional 24 h
and rescreened. MPCpr was recorded as the lowest antibiotic
concentration that allowed no growth. This measurement
was followed by a second measurement that utilized linear
drug concentration increments that did not exceed 20% per
sequential increase. These determinations were performed in
triplicates.
Determination of Protein Binding In Vitro
Protein binding studies were performed in triplicate using
Amicon Centrifree Micropartition devices (Millipore, Bedford,
MA, USA) with 10000 Nominal Molecular Weight Limit
according to the manufacturer’s package insert. Pooled
uninfected TCF was spiked with 0.05, 0.1, 0.5, 1, and 2 μg/mL
marboﬂoxacin. The concentrations were selected based on
TCF concentration proﬁles of the doses that were utilized
in the PD studies. Five hundred micro liter was added into
a ultraﬁltration device and then contrifugated at 4000 g for
45 min at 25◦C to generate an ultraﬁltrate of ∼250 μl. Protein
binding of marboﬂoxacin was also determined in bovine serum
spiked with the same concentration as TCF, but in this case,
protein-bound drug was removed by ultracentrifugation at
12000 g for 45 min at 25◦C. The ultraﬁltrate was frozen at−20◦C
until assayed.
The percentage of protein bound fraction (%PB)
was calculated according to the following equation:
%PB = (initial concentration-ultraﬁltrate concentration)/initial
concentration × 100%. The drug free fraction (fu) = 1−%PB.
Animal
Eighteen female calves of Luxi Yellow Cattle (∼8 months with a
mean weight ± SD of 145 ± 24 kg) were used in the study. All
animal studies were approved by the animal research committees
of the South China Agriculture University. The animals were
maintained in accordance with the American Association for
Accreditation of Laboratory Animal Care Criteria.
Pharmacokinetic Measurements
Eighteen calves were divided randomly into nine administration
groups (two calves, four tissue-cages/group), which received a
series of dosages such as 0, 0.3, 0.5, 0.8, 1.0, 1.3, 1.6, 2.0,
and 2.8 mg/kg of body weight once daily intramuscularly after
inoculation (−24 h). This series of dosages achieved values
of AUC24 h/MIC for bacteriostatic action, bactericidal action,
bacterial elimination by assuming that the PK parameter of
marboﬂoxacin is proportional to the dose (Aliabadi and Lees,
2002; Shan et al., 2014) and were determined by preliminary
experiments. TCF (0.5 ml) was removed from the wiﬄe balls by
percutaneous puncture at 0, 1, 3, 6, 9, 12, 24, 30, 36, and 48 h
after marboﬂoxacin administration. Fluid samples were clariﬁed
by centrifugation 6000 rpm for 10 min and stored at −20◦C.
The total concentration of marboﬂoxacin was determined by
high-performance liquid chromatography (HPLC; Aliabadi and
Lees, 2002; Shan et al., 2014). The lower LOD was 0.005 μg
/ml. Marboﬂoxacin quantitation from TCF and ultraﬁltrate
were linear within a range of 0.01–5 μg/ml. The recovery of
marboﬂoxacin was >80%, and relative standard deviations for
both interday and intraday were <10% in TCF.
Pharmacokinetic parameters obtained from the
marboﬂoxacin concentration data from each cage, including
area under the concentration-time curve over 24 h (AUC24 h),
and the peak drug concentration in TCF (Cmax), were calculated
by a non-compartment model using WinNonlin 6.2 software
(Pharsight Corporation, Mountain View, CA, USA) and
Microsoft Excel was used to estimate %T > MIC values.
Pharmacokinetic-Pharmacodynamic (PK/PD)
Analysis
By using the individual PK parameter data obtained from each
cage, the relationship between drug exposure and bacterial
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response was expressed according to the following parameters:
the ratio of peak drug concentration divided by MIC (Cmax/MIC)
or MPC (Cmax/MPC), the ratio of 24 h area under the
curve of the TCF concentration over MIC (AUC24 h/MIC)
or MPC (AUC24 h/MPC) and the percentage of the dosing
interval that TCF drug concentrations were above the MIC
or MPC (%T > MIC or %T > MPC). The correlation
between antimicrobial eﬀectiveness and each of the PK/PD
parameters were determined by non-linear regression analysis
(Origin software, Version 9.2). The in vivo PK/PD relationship
of marboﬂoxacin was described using sigmoid Emax model
WinNonLin 6.2 software. The equation was described as the
following: E = Emax−(Emax−E0) × CeN/(EC50N+ CeN), where
E is the antibacterial eﬀect, measured as the change in the
bacterial counts 24 h after administration from the injection
of marboﬂoxacin(Log10 CFU/mL), Emax is the change in the
infected tissue-cage between 0 and 24 h after the treatment
of saline. E0 is the maximum change after i.m administration
which represents the maximum antibacterial eﬀect. Ce is the
AUC24 h/MIC or AUC24h/MPC parameter. EC50 is the Ce value
required to achieve 50% of the Emax . N is the Hill coeﬃcient that
describes the steepness of the AUC24 h/MIC or AUC24 h/MPC-
eﬀectiveness curve.
Results
In Vitro Susceptibility Testing
The MIC and MPC of marboﬂoxacin against P. multocida was
0.075μg/mL, 0.3μg/mL, respectively, and the ratio of MPC/MIC
was 4. The MICs for the post-treatment isolates recovered from
tissue cages did not change 24 h after exposure to marboﬂoxacin
therapy.
Protein Binding In Vitro
The protein binding of marboﬂoxacin in TCF and serum
was 40 ± 7%, 52 ± 4%, respectively, when marboﬂoxacin
concentrations ranged from 0.05 to 2 μg/mL (Table 1).
Obviously, the characteristic of the protein binding was not
concentration dependent. The protein binding can account for
the diﬀerences in MIC determined in Mueller–Hinton broth
(MHB) and in biological ﬂuids such as serum, interstitial ﬂuid.
GenerallyMICMHB = fuMICbiological ﬂuids, where fu is the fraction
of unbound marboﬂoxacin in the biological ﬂuids.
TABLE 1 | The protein binding of marbofloxacin in TCF and serum in vitro.
Spiked concentration (µg/ml) In vitro Protein binding(X ± SD)
TCF∗ Serum
0.05 0.40 ± 0.08 0.52 ± 0.05
0.1 0.37 ± 0.09 0.53 ± 0.04
0.5 0.41 ± 0.07 0.49 ± 0.04
1 0.40 ± 0.06 0.51 ± 0.05
2 0.43 ± 0.08 0.55 ± 0.03
Total 0.40 ± 0.07 0.52 ± 0.04
∗TCF, tissue cage fluid.
Tissue-Cage Infection Model
All tissue cages were sterile before the start of the experiments,
and no severe illness or distress occurred during the experiment
period. However, an increase in the rectal temperature
(ﬂuctuation range from 38 to 40.8◦C) was noted in all calves
during the experiments and The main inﬂammation reaction
is swelling through macroscopic observation, and touching the
skin around the infected tissue cages, the performance of the
pain and febrile was observed 12 h after inoculation. A total
of four tissue cages in three calves were excluded because of
hemorrhaging.
The geometric mean bacterial counts in TCF from the cages at
24 h after inoculation increased to 8.12 ± 0.31 log CFU/mL from
∼5× 106 CFU/mL. The geometric mean for all non-treated cages
at the end of the experience (48 h) was 8.83 ± 0.17 log CFU/mL.
Marbofloxacin In Vivo Antibacterial Activity
The in vivo antibacterial activity of marboﬂoxacin against
P. multocida (CVCC 1669) had a relatively good eﬀectiveness
9 h after i.m administration, but subsequently only a slight
reduction or inhibitory eﬀect as shown in Figure 2. No re-growth
occurred within 24 h exposure after treatment. The doses
required to decline by ∼4 log10 CFU/mL ranged from 1.6
to 2.8 mg/kg, whereas the mean bacterial counts in TCF of
untreated controls increased by ∼0.7 log10 CFU/mL. Although
bacterial count presented a downward trend after administration
at relatively lower doses, the local inﬂammatory reactions
(e.g., febrile, swelling and festering) become more serious.
Considerable variation in the bacterial count among tissue cages
after administration at various doses was observed. This is due
to infection that inﬂuences vascular supply diﬀerently and other
factors that determine the elimination rate from the tissue cages.
This was consistent with the observation for other antimicrobials
(Greko et al., 2003a,b).
Correlation of PK/PD Parameters with
Effectiveness
The relationships between the antibacterial eﬀectiveness
(log10 CFU/mL: a reduction of the count of P. multocida
FIGURE 2 | In vivo antimicrobial activity of marbofloxacin against
Pasteurella multocida in tissue-cage model after i.m administration at
various doses. Bacterial counts in tissue-cage fluid was monitored at 0, 3, 6,
9, and 24 h after the treatment of marbofloxacin. Data for SE of the mean
values were excluded for clarity.
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(CVCC 1669) after marboﬂoxacin treatment compared to
before treatment) and each of the PK/PD parameters are
shown in Figures 3 and 4. The parameter AUC24 h/MIC and
AUC24 h/MPC correlated signiﬁcantly with eﬀectiveness
(R2 = 85.14%), whereas regression of the other
PK/PD parameters versus the antibacterial eﬀectiveness
(log10 CFU/mL) gave poor correlation (R2 = 68.02% for
the Cmax/MIC and Cmax/MPC ratio, R2 = 39.42%, 57.62% for
%T > MIC, %T > MPC, respectively).
Magnitudes of PK/PD Parameters Determining
Antimicrobial Effectiveness
The proﬁle of Sigmoid Emax model describing the relationship
of antimicrobial eﬀectiveness and the AUC24h/MIC or
AUC24h/MPC parameter is presented in Figure 5. The values
of AUC24h/MIC and AUC24 h/MPC for 1.5 log10 CFU/mL
reduction (50% maximum response), 3 log10 CFU/mL reduction
(90% maximum response) were 18.60, 50.65 h and 4.67, 12.89 h,
respectively (Table 2). The slope of the AUC24 h/MIC ratio
and AUC24 h/MPC ratio versus eﬀectiveness was 1.92 and 1.85,
respectively.
Discussion
The understanding of PK/PD relationships of antimicrobials, and
implications for rational dose setting, has increased considerably.
However, most of the researches have been focused on human
medicine. While it is probable that the general results are also
applicable to the major animal species in veterinary medicine,
the antimicrobial-bacterial combinations diﬀer among animal
species, due to diﬀerence in PK parameters (Zak and O’Reilly,
1991). So far, a variety of models have been expanding this
area in veterinary medicine, such as in vitro dynamic model,
ex vivo integrated model and the neutropenic murine model
and so on(Andes and Craig, 2002a; MacGowan and Bowker,
2002; Mouton et al., 2005). Recently, tissue cage implanted
subcutaneously models have been extensively developed to
assist in identifying and deﬁning the PK/PD parameter of
antimicrobials (Greko et al., 2003a; Cui et al., 2006; Ni et al.,
2014).
The PK/PD relationships of diﬀerent ﬂuoroquinolones
against diﬀerent bacteria have been extensively investigated
both in in vitro dynamic model and in the diﬀerent animal
FIGURE 3 | Relationships between PK/PD parameters based MIC for Pasteurella multocida (CVCC1669) and log10 CFU/mL after 24 h of therapy in
the infected tissue-cage. The lines represent the best model fits of the data. R2 is the correlation coefficient.
FIGURE 4 | Relationships between PK/PD parameters based MPC for Pasteurella multocida (CVCC1669) and log10CFU/mL after 24 h of therapy in
the infected tissue-cage. The lines represent the best model fits of the data. R2 is the correlation coefficient.
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FIGURE 5 | Plots of AUC24 h/MIC or AUC24h/MPC ratio versus the difference of bacterial counts (log10 CFU/mL) for Pasteurella multocida
(CVCC1669) 24 h after i.m administration at various doses in the infected tissue-cage. The line represents the curve of predicted values, based on the
Sigmoid Emax model, and the circles are the values for the individual tissue-cage.
TABLE 2 | In vivo PK/PD integration data obtained for marbofloxacin after
i.m administrations at various doses in calves (n = 18).
PK/PD integration Value
Emax (Log10 (CFU/ml)) 0.74
E0 (Log10 (CFU/ml)) −3.57
Emax−E0 (Log10 (CFU/ml)) 4.28
AUC24h/MIC EC50 (h) 18.60
AUC24h/MIC3log10CFU reduction(h) 50.65
AUC24h/MPC EC50(h) 4.67
AUC24h/MPC3log10CFU reduction(h) 12.89
Slope(N) 1.85
models. Most studies demonstrated that the AUC24 h/MIC ratio
correlates signiﬁcantly with the antimicrobial eﬀectiveness while
the Cmax/MIC ratio is associated with suppression of bacterial
resistance (Drusano et al., 1993, 1998). In the present study, we
found that AUC24 h/MIC is the PK/PD parameter predicting
the antimicrobial eﬀectiveness by non-linear regression analysis.
The level of AUC24 h/MIC, that produced 50 and 90% of the
maximum response corresponding to 1.5 log10 CFU/mL and
3 log10 CFU/mL reduction, were 18.60 and 50.65 h, respectively.
The ﬁgures were lower than that for 90% maximal response
reported in studies on marboﬂoxacin against P. multocida by ex
vivo PK/PD integrated models while our studies adopted a higher
inoculum (∼8 log10CFU/mL) compared with other investigation
(∼6 log10 CFU/ml) at the start of experiments (Aliabadi and
Lees, 2002; Sidhu et al., 2011; Potter et al., 2013; Shan et al., 2014).
One of the explanations might be the importance of host defense
mechanisms during treatment of infections caused by bacteria
(Blaser et al., 1987). Likewise, the magnitude of the AUC24 h/MIC
required for similar eﬀectiveness is still lower than that observed
in a neutropenic mouse pneumonia model (unpublished
observations). The diﬀerences are caused by the shape of the
marboﬂoxacin concentration proﬁle in vivo, for the shape has
an vital impact on antibacterial activity and the post antibiotic
eﬀect (PAE) in vivo, then contributes to the diﬀerent magnitude
of PK/PD parameter required similar eﬀectiveness (Andes
and Craig, 2002a; Rees et al., 2014). Besides, lower or higher
ﬁgures have also been reported for diﬀerent combinations of
ﬂuoroquinolones and bacterial species, both in in vitro dynamic
models (Madaras-Kelly et al., 1996; MacGowan et al., 2000) and
in murine thigh or lung infection models (Andes and Craig,
2002b), even in tissue cage models (Greko et al., 2003b), Jacobs
(2001) showed that for concentration-dependent killing, the
unbound serum AUC24 h/MIC ratio need to be >25–30 h for less
severe infections or in immunocompromised patient. Thomas
et al. (1998) found that an AUC24 h/MIC ratio of 125 h correlates
with bacteriological cure for ﬂuoroquinolones in human clinical
trials and in laboratory animal infection models. For studies
using tissue cages, Greko et al. (2003b) found that the values of
AUC24 h/MIC producing 50 and 80% of the maximum response
for danoﬂoxacin against Mannheimia haemolytica are 101 and
244 h, respectively. Diﬀerences in study design, such as choice of
measure of antimicrobial eﬀectiveness, diﬀerences in inoculum
at the start of experiments, PK parameters characteristic and
diﬀerent combination of antimicrobial and bacterial species,
may explain the diﬀerent values for antimicrobial eﬃcacy
reported in diﬀerent studies (MacGowan and Bowker, 2002;
Greko et al., 2003a). Besides, diﬀerent bacterial isolates may
vary the magnitude of AUC24 h/MIC required for antimicrobial
eﬀectiveness.
The most important risk factor for emergence of resistance
is repeated exposure to suboptimal concentration of antibiotics
(Zhao and Drlica, 2001). Some investigations indicated that the
higher Cmax/MIC ratio (∼10 h or greater) is associated with
a lower incidence of bacterial resistance (Drusano et al., 1993;
Thorburn and Edwards, 2001). However, Drlica and Zhao (2007)
proposed that the MPC is a possible application of the PK/PD
approach for optimization of antimicrobial treatment regimens.
Frontiers in Microbiology | www.frontiersin.org 6 July 2015 | Volume 6 | Article 759
Cao et al. Antimicrobial activity of marbofloxacin against Pasteurella multocida
Then, in vitro dynamic model and in vivo model studies
(Olofsson et al., 2007; Liang et al., 2011; Ni et al., 2014) suggested
that MPC-based PK/PD indices have an advantage over MIC-
based indices for maximizing eﬃcacy and minimizing selection
of resistance. In our study, the value of AUC24 h/MPC ratio that
is required near maximum eﬀect was ∼13 h, while bacterial
susceptibility is unchanged. In a previous study, Escherichia
coli was treated with ciproﬂoxacin(Olofsson et al., 2007) and
Staphylococcus aureus was treated with levoﬂoxacin (Liang et al.,
2011) for 24 h in an in vitro dynamic model, AUC24 h/MPC = 22
and 25 h correlated with restricted outgrowth of resistant mutant
subpopulations, respectively. In the infected rabbit models, in
vivo AUC24 h/MPC threshold corrected for protein binding of
levoﬂoxacin was 18 h for Staphylococcus aureus (Cui et al., 2006),
and 14 h for E. coli (Ni et al., 2014), respectively. The diﬀerences
were caused by diﬀerent combination of antimicrobial and
bacterial species. So far, because more and more studies indicated
that the MPC-based PK/PD indices might be a more reliable
PD parameter on evaluating antimicrobial dosing regimen,
thus, our study made an attempt to provide the magnitude
of AUC24 h/MPC required for diﬀerent eﬀectiveness for other
researcher’s reference.
It is generally accepted that only the free fraction of
antimicrobial in the interstitial ﬂuid remains active against
extracellular bacteria, but the bound fraction is generally
recognized to be microbiologically inactive. Even if plasma
and interstitial ﬂuid levels of antibiotics do not always
equilibrate, the concentration of unbound antibiotic in plasma
approximates its free concentration in the extracellular space
(fuplasmaAUCplasma = fuinterstitial ﬂuidAUCinterstitial ﬂuid, that
is 48%AUCplasma = 60%AUCinterstitial ﬂuid; Drusano et al.,
1998). Applying the value of AUCplasma = 22.24 h•μg/mL
following single intramuscular administration of 2 mg/kg body
weight in diseased calves (Ismail and El-Kattan, 2007), we
can calculate AUCinterstitial ﬂuid = 17.79 h•μg/mL at the
infection site. Therefore, the PK/PD breakpoint based on
MIC determined MHB can be calculated using following
formula: AUCinterstitial ﬂuid÷AUC24 h/MIC for a reduction of
3 log10CFU/mL × fuinterstitial ﬂuid (Jacobs, 2001). Thus, we
can conclude that the PK/PD breakpoint based on MIC
determined MHB was 0.21 mg/kg, that is, the recommend
dosing regimen of i.m administration at 2 mg/kg body weight
per day will likely to be eﬀective against P. multocida with
marboﬂoxacin MICs of up to 0.21 mg/kg. A survey of
marboﬂoxacin susceptibility of bacteria isolated from cattle
with respiratory disease and mastitis in Europe in 2002–2008
indicated that MIC90 value of marboﬂoxacin against P. multocida
is 0.12 mg/kg (Kroemer et al., 2012), we can infer that the
recommended dosing regimen of marboﬂoxacin is likely very
good eﬀective against 90% or greater P. multocida isolates from
bovine respiratory pathogen. Abo-El-Sooud and Goudah (2010)
validated this point that the recommended dosing regimen of
marboﬂoxacin has the favorable PD characteristics in diseased
rabbits.
The PK/PD integration methods by tissue cage models display
the advantage of allowing evaluation of antimicrobial activity
and optimization of dosage regimens in the presence of the host
defense, especially in the target animal of veterinary interest. In
our study, we indirectly conclude that 2 mg/kg/day is likely to be
eﬀective against 90% or greater P. multocida isolates, according
to AUC24 h/MIC values required for eﬀectiveness at the infection
site and MIC90 value of marboﬂoxacin against P. multocida
(Kroemer et al., 2012). Of course, the results of this model need to
be validated by clinical trials in relevant animal species; however,
it is still a critical step between in vitro studies and clinical
trials for the further understanding of PK/PD relationships of
antimicrobials.
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